Literature DB >> 26578351

Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage.

Joseph M Zabramski1, M Yashar S Kalani2, Aristotelis S Filippidis2, Robert F Spetzler2.   

Abstract

BACKGROUND: Cerebral cavernous malformations are more common than generally thought, affecting approximately 1 in every 250 adults. Most of these lesions are asymptomatic or have a relatively benign course, but a small minority behave aggressively and present with recurrent episodes of symptomatic hemorrhage. A safe and effective medical treatment option for the management of this latter group would be useful. Propranolol has recently been shown to be effective in the treatment of infantile hemangioma, a close pathologic counterpart of cavernous malformations. These results suggest a potential role for propranolol treatment in the management of patients with symptomatic cavernous malformations.
METHODS: Low-dose propranolol (20 mg, three times daily) was used to treat 2 adult female patients in their mid- to late fifties, both of whom had symptomatic cavernous malformations and a history of repeated hemorrhage. Serial magnetic resonance imaging studies after the initiation of propranolol demonstrated regression of the lesions and no evidence of recurrent hemorrhage.
CONCLUSIONS: Propranolol may offer a safe and effective treatment for patients who have cavernous malformations with symptomatic hemorrhage. Additional studies are needed to confirm these findings.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Beta-blockers; Cavernous malformations; Cerebral cavernous malformations; Hemorrhage; Propranolol; Symptomatic

Mesh:

Substances:

Year:  2015        PMID: 26578351     DOI: 10.1016/j.wneu.2015.11.003

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  13 in total

Review 1.  Cavernous angiomas: deconstructing a neurosurgical disease.

Authors:  Issam A Awad; Sean P Polster
Journal:  J Neurosurg       Date:  2019-07-01       Impact factor: 5.115

2.  Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).

Authors:  Sean P Polster; Ying Cao; Timothy Carroll; Kelly Flemming; Romuald Girard; Daniel Hanley; Nicholas Hobson; Helen Kim; James Koenig; Janne Koskimäki; Karen Lane; Jennifer J Majersik; Nichol McBee; Leslie Morrison; Robert Shenkar; Agnieszka Stadnik; Richard E Thompson; Joseph Zabramski; Hussein A Zeineddine; Issam A Awad
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

3.  A 5-year outcome of propranolol for the treatment of paediatric intracranial cavernoma: case report and a review of the literature.

Authors:  Jakov Tiefenbach; Jay J Park; Chandrasekaran Kaliaperumal
Journal:  Childs Nerv Syst       Date:  2022-07-14       Impact factor: 1.532

Review 4.  Tailored Treatment Options for Cerebral Cavernous Malformations.

Authors:  Jessa E Hoffman; Blake Wittenberg; Brent Morel; Zach Folzenlogen; David Case; Christopher Roark; Samy Youssef; Joshua Seinfeld
Journal:  J Pers Med       Date:  2022-05-20

5.  Calm the raging hormone - A new therapeutic strategy involving progesterone-signaling for hemorrhagic CCMs.

Authors:  Jun Zhang; Johnathan S Abou-Fadel
Journal:  Vessel Plus       Date:  2021-07-05

6.  Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease.

Authors:  Virginia Albiñana; Rosa María Jiménez Escribano; Isabel Soler; Luis Rodríguez Padial; Lucia Recio-Poveda; Karina Villar Gómez de Las Heras; Luisa María Botella
Journal:  Orphanet J Rare Dis       Date:  2017-06-29       Impact factor: 4.123

Review 7.  Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel.

Authors:  Amy Akers; Rustam Al-Shahi Salman; Issam A Awad; Kristen Dahlem; Kelly Flemming; Blaine Hart; Helen Kim; Ignacio Jusue-Torres; Douglas Kondziolka; Cornelia Lee; Leslie Morrison; Daniele Rigamonti; Tania Rebeiz; Elisabeth Tournier-Lasserve; Darrel Waggoner; Kevin Whitehead
Journal:  Neurosurgery       Date:  2017-05-01       Impact factor: 4.654

8.  Signalling through cerebral cavernous malformation protein networks.

Authors:  Valerie L Su; David A Calderwood
Journal:  Open Biol       Date:  2020-11-25       Impact factor: 6.411

9.  Novel Murine Models of Cerebral Cavernous Malformations.

Authors:  Matthew R Detter; Robert Shenkar; Christian R Benavides; Catherine A Neilson; Thomas Moore; Rhonda Lightle; Nicholas Hobson; Le Shen; Ying Cao; Romuald Girard; Dongdong Zhang; Erin Griffin; Carol J Gallione; Issam A Awad; Douglas A Marchuk
Journal:  Angiogenesis       Date:  2020-07-24       Impact factor: 9.596

10.  Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial.

Authors:  Silvia Lanfranconi; Elisa Scola; Giulio Andrea Bertani; Barbara Zarino; Roberto Pallini; Giorgio d'Alessandris; Emanuela Mazzon; Silvia Marino; Maria Rita Carriero; Emma Scelzo; Giuseppe Faragò; Marco Castori; Carmela Fusco; Antonio Petracca; Leonardo d'Agruma; Laura Tassi; Piergiorgio d'Orio; Maria Grazia Lampugnani; Enrico Bjorn Nicolis; Antonella Vasamì; Deborah Novelli; Valter Torri; Jennifer Marie Theresia Anna Meessen; Rustam Al-Shahi Salman; Elisabetta Dejana; Roberto Latini
Journal:  Trials       Date:  2020-05-12       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.